A Phase 2 interventional study of Neramexane mesylate in Nystagmus, Congenital Idiopathic and Nystagmus, Acquired, sponsored by Merz Pharmaceuticals GmbH. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2009-11-26.
Sponsored by Merz Pharmaceuticals GmbH (part of Merz Pharma) · Phase 2, Interventional, and Treatment
The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN) in comparison to placebo. In addition, a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be included; this subgroup will be analyzed in an exploratory manner only.
27 studies on the registry are indexed under Nystagmus, Pathologic; 3 are open to participants now.
This study's planned enrollment of 48 is close to the median of 48 across 17 interventional studies indexed under Nystagmus, Pathologic.
Browse Nystagmus, Pathologic studies →Merz Pharmaceuticals GmbH is the lead sponsor of 61 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Neramexane mesylate
Drug: Neramexane mesylate
2 double-blind, cross-over treatment periods of 7 weeks separated by a wash-out phase, up to 75 mg Neramexane mesylate per day
Also known as: - verum, placebo, - placebo, verum
Visual acuity
Time frame: Screening, Baseline, Week 3, 7, 11, 14, 18, and Follow-up
nystagmus intensity, expanded nystagmus acuity function, reading ability, questionnaires, safety parameter
This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Neramexane mesylate